Drug profile · INN
ensifentrine
OHTUVAYRE
ensifentrine (OHTUVAYRE) is a phosphodiesterase 4 inhibitor. Route of administration: inhalation. Current US regulatory status: approved.
Drug details — ensifentrine
- US status
- approved
- Class
- Respiratory system (R03)
- Route
- INHALATION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
ensifentrine (OHTUVAYRE) is a phosphodiesterase 4 inhibitor. Route of administration: inhalation. Current US regulatory status: approved.
Key facts
Mechanism of action
Phosphodiesterase 4 inhibitor
Primary target: Phosphodiesterase 3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ensifentrine?
ensifentrine (OHTUVAYRE) is a phosphodiesterase 4 inhibitor. Route of administration: inhalation. Current US regulatory status: approved.
What is the brand name for ensifentrine?
OHTUVAYRE is a marketed brand name for ensifentrine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ensifentrine?
ensifentrine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.